122 related articles for article (PubMed ID: 33682591)
1. Bilateral periorbital leukemia cutis presenting as suspected cellulitis.
Gupta L; Levoska MA; Sharma T; Honda K; Prendes MA
Orbit; 2022 Aug; 41(4):506-508. PubMed ID: 33682591
[TBL] [Abstract][Full Text] [Related]
2. Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
Kallen ME; Koka R; Singh Z; Sanchez-Petitto G; Zaman QU; Yared JA; Duong VH
Leuk Res; 2020 Sep; 96():106406. PubMed ID: 32604058
[No Abstract] [Full Text] [Related]
3. Wells Syndrome Presenting as Atypical Periorbital Cellulitis.
Vongsachang H; Bleicher ID; Reshef ER; Stagner AM; Wolkow N
Ophthalmic Plast Reconstr Surg; 2022 Nov-Dec 01; 38(6):e167-e170. PubMed ID: 35699219
[TBL] [Abstract][Full Text] [Related]
4. Recurrent leukemia cutis in acute myeloblastic leukemia.
Girgis RE; Terebelo H; Maeda K
Henry Ford Hosp Med J; 1989; 37(2):76-8. PubMed ID: 2606734
[TBL] [Abstract][Full Text] [Related]
5. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
6. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
7. Bullous leukemia cutis mimicking facial cellulitis.
Caldato Lde S; Britto Jde S; Niero-Melo L; Miot HA
An Bras Dermatol; 2016 Apr; 91(2):248-9. PubMed ID: 27192532
[TBL] [Abstract][Full Text] [Related]
8. Acute dacryocystitis as a presenting sign of pediatric leukemia.
Wirostko WJ; Garcia GH; Cory S; Harris GJ
Am J Ophthalmol; 1999 Jun; 127(6):734-6. PubMed ID: 10372893
[TBL] [Abstract][Full Text] [Related]
9. Sweet's syndrome in acute myelogenous leukemia presenting as periorbital cellulitis with an infiltrate of leukemic cells.
Morgan KW; Callen JP
J Am Acad Dermatol; 2001 Oct; 45(4):590-5. PubMed ID: 11568752
[TBL] [Abstract][Full Text] [Related]
10. Periorbital cellulitis as the initial presentation of acute lymphoblastic leukaemia.
Han-Menz C; Kozgar SAM; Rana MS
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38749518
[TBL] [Abstract][Full Text] [Related]
11. Multi-resistant
Kvopka M; Kingston E; Nguyen DDH; Tong JY; Kirk HL; Whyte CM; Dalgliesh JD; Danks JJ
Orbit; 2023 Aug; 42(4):441-444. PubMed ID: 35075984
[TBL] [Abstract][Full Text] [Related]
12. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
[TBL] [Abstract][Full Text] [Related]
14. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
15. Acute myelogenous leukemia mimicking fulminant periorbital cellulitis.
Bagheri A; Abrishami A; Karimi S
J Ophthalmic Vis Res; 2013 Oct; 8(4):380-2. PubMed ID: 24653827
[TBL] [Abstract][Full Text] [Related]
16. Leukemia Cutis in Relapsed Acute Myeloid Leukemia: A Call for Distinct Classification.
Nahm WJ; Juarez M; Abdul-Hay M; Bhatt A; Meehan SA; Shvartsbeyn M
Am J Case Rep; 2024 May; 25():e943577. PubMed ID: 38760926
[TBL] [Abstract][Full Text] [Related]
17. Chronic Lymphocytic Leukemia Presenting as Bilateral Periorbital Edema Treated With Low-dose Radiation Therapy.
Spadaro JZ; Chow R; Sinard JH; Watsky K; Habib L
Ophthalmic Plast Reconstr Surg; 2023 May-Jun 01; 39(3):e78-e81. PubMed ID: 36852835
[TBL] [Abstract][Full Text] [Related]
18. Toxic erythema of chemotherapy following leukemia cutis.
Kaskas N; DiGiorgio C; Vincent B; Walia S; Mermilliod J
J La State Med Soc; 2014; 166(6):236-8. PubMed ID: 25978658
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
20. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.
Myers RA; Wirth S; Williams S; Kiel PJ
J Adv Pract Oncol; 2018; 9(4):435-440. PubMed ID: 30719396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
